Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by analysts at
Weiss Ratings from a "sell (d-)" rating to a "hold (c-)" rating.